Gb Virus C Infection is Associated with a Reduced Rate of Reactivation of Latent HIV and Protection against Activation-Induced T-Cell Death

Abstract

Background

GB virus C (GBV-C) coinfection is associated with reduced immune activation and a block in CD4⁺ T-cell proliferation following interleukin-2 (IL-2) therapy in HIV-infected individuals. We examined peripheral blood mono-nuclear cells (PBMCs) from HIV-infected subjects with and without GBV-C viraemia to determine if GBV-C correlated with reactivation of latent HIV, T-cell proliferation or T-cell survival following in vitro activation with phytohaemag-glutinin A and IL-2 (PHA/IL-2).

Methods

HIV-infected subjects whose HIV viral load was suppressed on combination antiretroviral therapy (cART) for >6 months were studied. PBMCs were cultured with and without PHA/IL-2 and monitored for HIV reactivation, proliferation and survival. GBV-C viraemia and in vitro replication were detected by real-time RT-PCR. HIV reactivation was determined by measuring HIV p24 antigen in culture supernatants. Proliferation was measured by counting viable cells and survival measured by flow cytometry.

Results

Of 49 HIV-infected individuals, 26 had GBV-C viraemia. Significantly less HIV reactivation and PBMC proliferation following in vitro activation with PHA/IL-2 was observed in samples from GBV-C viraemic subjects compared with non-viraemic controls. Following 5 weeks in culture, GBV-C replication was associated with preservation of CD4⁺ and CD8⁺ T-cells compared with non-viraemic controls.

Conclusions

GBV-C appears to inhibit immune activation and IL-2 signalling pathways, which might contribute to a reduction in reactivation of latent HIV from cellular reservoirs. In addition, GBV-C viraemia was associated with a reduction in activation-induced T-cell death. GBV-C-associated T-cell effects could contribute to the observed protective effect of GBV-C coinfection in HIV-infected individuals.

References

Stapleton

J.T.

GB virus type C/hepatitis G virus. Semin Liver Dis 2003; 23: 137–148.

Mohr

E.L.

, Stapleton

J.T.

GB virus type C interactions with HIV: the role of envelope glycoproteins. J Viral Hepat 2009; 16: 757–768.

Heringlake

, Ockenga

, Tillmann

H.L.

GB virus C/hepatitis G virus infection: a favorable prognostic factor in human immunodeficiency virus-infected patients?

J Infect Dis 1998; 177: 1723–1726.

Toyoda

, Fukuda

, Hayakawa

, Takamatsu

, Saito

Effect of GB virus C/hepatitis G virus coinfection on the course of HIV infection in hemophilia patients in Japan. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17: 209–213.

Lefrère

J.J.

, Ferec

, Roudot-Thoraval

GBV-C/ hepatitis G virus (HGV) RNA load in immunodeficient individuals and in immunocompetent individuals. J Med Virol 1999; 59: 32–37.

Yeo

A.E.

, Matsumoto

, Hisada

, Shih

J.W.

, Alter

H.J.

, Goedert

J.J.

Effect of hepatitis G virus infection on progression of HIV infection in patients with hemophilia. Multicenter Hemophilia Cohort Study. Ann Intern Med 2000; 132: 959–963.

Tillmann

H.L.

, Heiken

, Knapik-Botor

Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med 2001; 345: 715–724.

Xiang

, Wunschmann

, Diekema

D.J.

Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med 2001; 345: 707–714.

Nunnari

, Nigro

, Palermo

Slower progression of HIV-1 infection in persons with GB virus C co-infection correlates with an intact T-helper 1 cytokine profile. Ann Intern Med 2003; 139: 26–30.

10.

Williams

C.F.

, Klinzman

, Yamashita

T.E.

Persistent GB virus C infection and survival in HIV-infected men. N Engl J Med 2004; 350: 981–990.

11.

Badley

A.D.

, Parato

, Cameron

D.W.

Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. Cell Death Differ 1999; 6: 420–432.

12.

Alimonti

J.B.

, Ball

T.B.

, Fowke

K.R.

Mechanisms of CD4⁺ T lymphocyte cell death in human immunodeficiency virus infection and AIDS. J Gen Virol 2003; 84: 1649–1661.

13.

Hunt

P.W.

, Martin

J.N.

, Sinclair

T cell activation is associated with lower CD4⁺ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187: 1534–1543.

14.

Grossman

, Meier-Schellersheim

, Paul

W.E.

, Picker

L.J.

Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat Med 2006; 12: 289–295.

15.

Moir

, Fauci

A.S.

B cells in HIV infection and disease. Nat Rev Immunol 2009; 9: 235–245.

16.

Giorgi

J.V.

, Hultin

L.E.

, McKeating

J.A.

Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179: 859–870.

17.

Hazenberg

M.D.

, Otto

S.A.

, van Benthem

B.H.

Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003; 17: 1881–1888.

18.

Dockrell

D.H.

, Badley

A.D.

, Algeciras-Schimnich

Activation-induced CD4⁺ T cell death in HIV-positive individuals correlates with Fas susceptibility, CD4⁺ T cell count, and HIV plasma viral copy number. AIDS Res Hum Retroviruses 1999; 15: 1509–1518.

19.

Geeraert

, Kraus

, Pomerantz

R.J.

Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu Rev Med 2008; 59: 487–501.

20.

Siliciano

J.D.

, Kajdas

, Finzi

Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4⁺ T cells. Nat Med 2003; 9: 727–728.

21.

Dornadula

, Zhang

, VanUitert

Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999; 282: 1627–1632.

22.

Palmer

, Maldarelli

, Wiegand

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008; 105: 3879–3884.

23.

Rong

, Perelson

A.S.

Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLOS Comput Biol 2009; 5: e1000533.

24.

Günthard

H.F.

, Wong

J.K.

, Spina

C.A.

Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis 2000; 181: 522–531.

25.

Tobin

N.H.

, Learn

G.H.

, Holte

S.E.

Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol 2005; 79: 9625–9634.

26.

Wolschendorf

, Duverger

, Jones

Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction. J Virol 2010; 84: 8712–8720.

27.

Stevenson

, Stanwick

T.L.

, Dempsey

M.P.

, Lamonica

C.A.

HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J 1990; 9: 1551–1560.

28.

Copeland

K.F.

Modulation of HIV-1 transcription by cytokines and chemokines. Mini Rev Med Chem 2005; 5: 1093–1101.

29.

Maidana-Giret

M.T.

, Silva

T.M.

, Sauer

M.M.

GB virus type C infection modulates T-cell activation independently of HIV-1 viral load. AIDS 2009; 23: 2277–2287.

30.

Stapleton

J.T.

, Chaloner

, Zhang

GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy. AIDS 2009; 23: 605–610.

31.

Rodriguez

, Woolley

, Lederman

M.M.

, Zdunek

, Hess

, Valdez

Effect of GB virus C coinfection on response to antiretroviral treatment in human immunodeficiency virus-infected patients. J Infect Dis 2003; 187: 504–507.

32.

Souza

I.E.

, Zhang

, Diaz

R.S.

, Chaloner

, Klinzman

, Stapleton

J.T.

Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians. HIV Med 2006; 7: 25–31.

33.

Antonucci

, Girardi

, Cozzi-Lepri

Response to HAART and GB virus type C coinfection in a cohort of antiretroviral-naive HIV-infected individuals. Antivir Ther 2005; 10: 109–117.

34.

George

S.L.

, Xiang

, Stapleton

J.T.

Clinical isolates of GB virus type C vary in their ability to persist and replicate in peripheral blood mononuclear cell cultures. Virology 2003; 316: 191–201.

35.

Xiang

, Klinzman

, McLinden

Characterization of hepatitis G virus (GB-C virus) particles: evidence for a nucleocapsid and expression of sequences upstream of the E1 protein. J Virol 1998; 72: 2738–2744.

36.

Xiang

, George

S.L.

, Wunschmann

, Chang

, Klinzman

, Stapleton

J.T.

Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1. Lancet 2004; 363: 2040–2046.

37.

Coiras

, Lopez-Huertas

M.R.

, Perez-Olmeda

, Alcami

Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol 2009; 7: 798–812.

38.

Wang

F.X.

, Xu

, Sullivan

IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005; 115: 128–137.

39.

George

S.L.

, Varmaz

, Stapleton

J.T.

GB virus C replicates in primary T and B lymphocytes. J Infect Dis 2006; 193: 451–454.

40.

Moenkemeyer

, Schmidt

R.E.

, Wedemeyer

, Tillmann

H.L.

, Heiken

GBV-C coinfection is negatively correlated to Fas expression and Fas-mediated apoptosis in HIV-1 infected patients. J Med Virol 2008; 80: 1933–1940.